Our Business

Phosphagenics Limited is a Melbourne-based biotechnology company which has developed a unique delivery technology based on tocopherol phosphate (Vitamin E phosphate).  This platform technology, known as TPM® is able to deliver actives and drugs into or through the skin.

Phosphagenics shares are listed on the Australian Securities Exchange (ASX: POH).  Phosphagenics ADR’s are also traded on the OTCQX in the USA.


Breaking News

28 July 2014


  • Next phase of the TPM®/Oxymorphone clinical development program has commenced
  • TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4/2014
  • Upcoming opioid pain patch trials fully funded
Phosphagenic provides the following update on its opioid transdermal patch programs after its recent announcement of a $19.3 million capital raising.  This update is intended to provide clarity on how the Company will apply the newly raised funds to progress the development of its lead pharmaceutical assets.

11 July 2014


  • Includes $3 million Share Purchase Plan
  • Upcoming opioid pain patch trials fully funded
Phosphagenic Limited has raised $19.3 million via a placement of $16.3 million to insitutional and sophisticated investors in Europe, USA, Asia and Australia and $3 million from a share purchase plan (SPP) to be offered to existing shareholders.  The placement of $16.3 million will be made in two tranches.

"This capital raising positions us strongly to fulfil our commercialisation objectives and fully funds our scheduled TPM®/opiod clinical trial programs.  The capital raised is earmarked for our pivotal TPM®/Oxymorphone Phase 2 clinical trial in the USA scheduled for the first half of 2015 and our upcoming TPM®/Oxycodone Phase 2 trial in Australia," said CEO, Harry Rosen.